Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor crucial for DNA repair.
• BRCA1 mutations are common in breast and ovarian cancers, making BRCA1 deficiency a therapeutic target.
• DNA repair deficiencies, like in BRCA1-mutated cancers, create vulnerabilities exploitable by certain drugs.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting class I histone deacetylases (HDAC) in BRCA1-deficient breast cancer.
• To elucidate the molecular mechanisms underlying the synthetic lethality observed between BRCA1 deficiency and HDAC inhibition.
• To evaluate the combined efficacy of HDAC inhibitors with other targeted therapies in BRCA1-mutated breast cancer models.

Main Methods:

• Utilized transcriptome profiling to identify molecular changes induced by HDAC inhibition.
• Validated the role of thioredoxin interaction protein (TXNIP) and reactive oxygen species (ROS) in mediating DNA damage.
• Conducted in vitro cell-based assays, in vivo animal experiments, and patient survival analysis.

Main Results:

• HDAC inhibition led to increased TXNIP expression and ROS-mediated DNA damage in breast cancer cells.
• BRCA1-deficient cells exhibited synthetic lethality with HDAC inhibition, undergoing preferential apoptosis.
• In vivo studies and patient data confirmed the synthetic lethality between BRCA1 and HDAC.
• Combination therapy with HDAC and bromodomain and extra-terminal motif (BET) inhibitors showed significant anticancer effects.

Conclusions:

• Class I HDAC inhibition represents a promising synthetic lethal strategy for BRCA1-deficient breast cancer.
• The mechanism involves enhanced TXNIP expression, ROS production, and subsequent DNA damage.
• Targeting epigenetic regulators like HDAC and BET offers a novel therapeutic avenue for BRCA1-mutated cancers.